OWC Pharmaceutical Research Corp. (OWCP)
OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: Feb 10, 2026

OWCP Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2018FY 2017FY 2016FY 2015FY 2014
Period Ending
Sep '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14
---0.05--
Gross Profit
---0.05--
Selling, General & Admin
2.152.864.112.011.384.87
Research & Development
0.990.710.440.140.270.16
Operating Expenses
3.143.574.552.151.655.03
Operating Income
-3.14-3.57-4.55-2.1-1.65-5.03
Interest Expense
-0.01-0.83-0.01--0-0.04
Interest & Investment Income
-----0
Currency Exchange Gain (Loss)
----0.02--
Other Non Operating Income (Expenses)
5.21-5.14--0.17--
EBT Excluding Unusual Items
2.07-9.53-4.56-2.29-1.65-5.07
Legal Settlements
-0.73-0.73----
Pretax Income
1.34-10.26-4.56-2.29-1.65-5.07
Net Income
1.34-10.26-4.56-2.29-1.65-5.07
Preferred Dividends & Other Adjustments
3.632.45----
Net Income to Common
-2.29-12.71-4.56-2.29-1.65-5.07
Shares Outstanding (Basic)
185148145968152
Shares Outstanding (Diluted)
185148145968152
Shares Change (YoY)
25.41%1.97%50.69%19.57%54.36%175.06%
EPS (Basic)
-0.01-0.09-0.03-0.02-0.02-0.10
EPS (Diluted)
-0.01-0.09-0.03-0.02-0.02-0.10
Free Cash Flow
-2.75-2.53-1.2-0.53-1.22-0.63
Free Cash Flow Per Share
-0.01-0.02-0.01-0.01-0.01-0.01
Gross Margin
---100.00%--
Operating Margin
----4196.15%--
Profit Margin
----4574.66%--
Free Cash Flow Margin
----1062.26%--
EBITDA
-3.13-3.56-4.55-2.09-1.64-5.03
D&A For EBITDA
0.010.010.010.010.010
EBIT
-3.14-3.57-4.55-2.1-1.65-5.03
Source: S&P Global Market Intelligence. Standard template. Financial Sources.